About this trial
This study will enroll 10,000 patients with obesity, with the participation of approximately 50 medical institutions nationwide. At baseline, demographic data, physical examinations, multiple laboratory tests (including complete blood count, urinalysis, liver/renal function, electrolytes, thyroid function panel \[3 items\], urine albumin/creatinine ratio, fasting glucose, fasting C-peptide, fasting insulin, HbA1c, blood lipids, etc.) and hepatic elasticity ultrasound will be performed. Patients will receive weight-loss therapy in routine clinical practice. Data on clinic visits, adverse events, and changes in therapeutic regimens will be centrally collected by investigators or their authorized representatives at Week 26 and Week 52.
Eligibility criteria
Qualifiers
Male or female patients aged 18 years or above
Diagnosed with overweight or obesity, with a BMI of ≥ 24 kg/m²
Willing and able to use weight management apps
Willing and able to provide a written informed consent for participating in the study
Disqualifiers
Having life-threatening comorbidities, with an expected lifespan of less than one year.
Participating in an interventional trial that requires informed consent.
Engaging in other organized weight loss programs or other clinical trials.
Researchers identify any situation that may endanger the safety or compliance of the subjects.
Trial design
Treatments tested in this trial
- Not listed